LYRA Lyra Therapeutics Inc
Price (delayed)
$0.0865
Market cap
$5.7M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.43
Enterprise value
-$2.49M
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose
Highlights
Lyra Therapeutics's gross profit has increased by 4.3% from the previous quarter
The company's revenue rose by 4.3% QoQ
Lyra Therapeutics's net income has decreased by 49% YoY but it has increased by 4.3% QoQ
The debt has grown by 28% year-on-year but it has declined by 2.7% since the previous quarter
LYRA's equity has dropped by 87% year-on-year and by 44% since the previous quarter
LYRA's quick ratio is down by 37% YoY and by 6% from the previous quarter
Key stats
What are the main financial stats of LYRA
Market
Valuations
Earnings
Shares outstanding
65.88M
Market cap
$5.7M
Enterprise value
-$2.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.49
Price to sales (P/S)
3.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.62
Revenue
$1.53M
Gross profit
$1.53M
Operating income
-$96.35M
Net income
-$93.44M
EBIT
-$93.4M
EBITDA
-$92.93M
Free cash flow
-$72.35M
Per share
Balance sheet
Liquidity
EPS
-$1.43
EPS diluted
-$1.43
Free cash flow per share
-$1.11
Book value per share
$0.18
Revenue per share
$0.02
TBVPS
$1.02
Total assets
$66.35M
Total liabilities
$54.75M
Debt
$34.38M
Equity
$11.59M
Working capital
$30.39M
Debt to equity
2.97
Current ratio
3.41
Quick ratio
3.37
Net debt/EBITDA
0.09
Margins
Efficiency
Dividend
EBITDA margin
-6,057.7%
Gross margin
100%
Net margin
-6,090.9%
Operating margin
-6,280.8%
Return on assets
-98%
Return on equity
-265.6%
Return on invested capital
-109.9%
Return on capital employed
-173.9%
Return on sales
-6,088.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LYRA stock price
How has the Lyra Therapeutics stock price performed over time
Intraday
-5.98%
1 week
1.88%
1 month
-47.58%
1 year
-98.4%
YTD
-58.09%
QTD
-31.51%
Financial performance
How have Lyra Therapeutics's revenue and profit performed over time
Revenue
$1.53M
Gross profit
$1.53M
Operating income
-$96.35M
Net income
-$93.44M
Gross margin
100%
Net margin
-6,090.9%
The net margin has dropped by 51% year-on-year but it has grown by 8% since the previous quarter
Lyra Therapeutics's net income has decreased by 49% YoY but it has increased by 4.3% QoQ
Lyra Therapeutics's operating margin has decreased by 46% YoY but it has increased by 9% QoQ
The company's operating income fell by 44% YoY but it rose by 5% QoQ
Growth
What is Lyra Therapeutics's growth rate over time
Valuation
What is Lyra Therapeutics stock price valuation
P/E
N/A
P/B
0.49
P/S
3.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.62
The EPS is down by 13% year-on-year but it is up by 4% since the previous quarter
LYRA's equity has dropped by 87% year-on-year and by 44% since the previous quarter
LYRA's price to book (P/B) is 73% less than its 5-year quarterly average of 1.9 and 71% less than its last 4 quarters average of 1.8
The price to sales (P/S) is 94% lower than the last 4 quarters average of 66.8
The company's revenue rose by 4.3% QoQ
Efficiency
How efficient is Lyra Therapeutics business performance
The return on assets has dropped by 89% year-on-year and by 15% since the previous quarter
The ROS has dropped by 51% year-on-year but it is up by 8% since the previous quarter
The return on equity has declined by 49% since the previous quarter
LYRA's return on invested capital is down by 42% year-on-year and by 18% since the previous quarter
Dividends
What is LYRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LYRA.
Financial health
How did Lyra Therapeutics financials performed over time
The total assets is 21% greater than the total liabilities
The total assets has dropped by 53% year-on-year and by 16% since the previous quarter
LYRA's quick ratio is down by 37% YoY and by 6% from the previous quarter
The debt is 197% greater than the equity
LYRA's equity has dropped by 87% year-on-year and by 44% since the previous quarter
The company's debt to equity has surged by 74% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.